T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets

Tuesday, October 7, 2014 | 9:00 a.m. - 9:55 a.m. | Twin Peaks North/South

New approaches in cancer immunology are achieving promising early-stage results through novel techniques for arming the body’s own T cells to have greater impact on reducing tumors and preventing the spread of disease. CAR-T methods that extract, reengineer, and reintroduce a given patient’s T cells provide highly personalized therapy but may be difficult to scale up. The interleukin enhancement approach motivates existing T cells to be more effective and may be easier to deliver but have less pervasive effects. Early signs also suggest significant side-effect risks that will need to be understood and reduced for T-cell therapies to progress to commercialization. This panel will review priorities in the field for tailoring T-cell approaches to different cancer types and improving therapy efficiencies.

Moderator

• Kristen Hege, MD, San Francisco Site Head, VP Translational Development, Hematology and Oncology, Celgene; Assistant Professor, Department of Medicine, University of California, San Francisco

Panelists

• David D. Chang, MD, PhD, EVP Research and Development, Chief Medical Officer, Kite Pharma
• Jonathan Lewis, MD, PhD, CEO and Director, ZIOPHARM Oncology
• Richard Morgan, PhD, Vice President, Immunotherapy, bluebird bio
• Timothy C. Rodell, MD, President and CEO and President, GlobeImmune

Gene Therapy Ascending? Today’s Advancements Over Past Hurdles

Wednesday, October 8, 2014 | 10:30 a.m. - 11:25 a.m. | Twin Peaks North/South

Since the great excitements and disappointments of gene therapy’s first clinical era, the 1990s, researchers have revised traditional approaches and developed innovative new techniques, including CRISPR/cas-9, to edit genes with greater speed and precision than ever before.  Across a wide range of diseases, gene therapy is showing traction with fresh clinical results and attracting more than $600 million in venture capital in the past two years.  However, real challenges remain in delivery of therapies in sufficient concentrations to achieve lasting results without introducing harmful complications.  This panel will discuss the variety of strategies companies are employing to reduce risks and improve patient outcomes. 

Moderator

• Eli A. Loots, PhD, Partner, Knobbe Martens

Panelists

• Katrine Bosley, CEO, Editas Medicine
• Thomas W. Chalberg, Jr., PhD, Founder and CEO, Avalanche Biotechnologies
• Harry E. Gruber, MD, Chairman, CEO and President, Tocagen

Electroceuticals and Digital Drug Delivery: Neurological Stimulation and Beyond

Wednesday, October 8, 2014 | 9:00 a.m. - 9:55 a.m. | Twin Peaks North/ South

Some of the most experienced executives in biotechnology have begun asking themselves, “Can we foresee the day of diminishing returns from research in traditional molecular biology?” These researchers are investigating alternative modalities of providing therapy that would combine electronic sensing with drug delivery or even stimulating the body through electricity alone to produce a desired response. These “electroceutical,” or “bioelectronics,” approaches have produced exciting results in early clinical trials, particularly related to insulin control and pain management. These innovative approaches suggest opportunities to rejuvenate past drug candidates that might show more effectiveness through the introduction of implantable electronic sensors combined with injectors. Marrying the fast-cycle nature of the electronics industry with the deliberate approach of clinical trials involves risks in execution but great potential returns. A recent National Institutes of Health announcement to create a $248 million fund to support research in electroceuticals endorses the hope in this integrative approach.

Moderator

• Scott Smith, Managing Director, Director of Life Sciences Investment Banking, Wedbush

Panelists

• Cheryl R. Blanchard, PhD, CEO, MicroCHIPS
• Juan-Pablo Mas, Partner, Action Potential Venture Capital
• Martha J. Morrell, MD, Chief Medical Officer, NeuroPace

Below is a list of companies that will be attending the 2015 BIO Investor Forum. 

All presenting company information and webcasts will be available through this page as we approach the conference.

Discovery Companies and Patient Advocacy Groups

Company	News & Information	Presentation Date, Time (PT), and Location
	Adjuvance Technologies Discovery | Website	Tuesday, 10/7 8:15 am Marina Room
	Aeglea BioTherapeutics Discovery | Website	Wednesday, 10/8 9:00 am Marina Room
	Allinky Biopharma Discovery | Website	Tuesday, 10/7 10:00 am Marina Room
	Atterocor Discovery | Website	Tuesday, 10/7 9:30 am Marina Room
	AuraSense Therapeutics Discovery | Website	Tuesday, 10/7 10:45 am Marina Room
	Bell Biosystems Discovery | Website	Wednesday, 10/8 8:30 am Marina Room
	BioKier Discovery | Website	Wednesday, 10/8 11:15 am Marina Room
	Bioniz LLC Discovery | Website	Tuesday, 10/7 2:45 pm Marina Room
	BioNovion B.V. Discovery | Website	Tuesday, 10/7 2:00 pm Marina Room
	Bionure Discovery | Website	Tuesday, 10/7 8:00 am Marina Room
	Biscayne Pharmaceuticals Discovery | Website	Tuesday, 10/7 2:15 pm Marina Room
	BNOAT Oncology Discovery | Website	Tuesday, 10/7 1:30 pm Marina Room
	CompuVax Discovery | Website	Wednesday, 10/8 10:30 am Marina Room
	Corbus Pharmaceuticals Discovery | Website	Wednesday, 10/8 9:30 am Marina Room
	Ennaid Therapeutics Discovery | Website	Tuesday, 10/7 2:30 pm Marina Room
	EternoGen Discovery | Website	Tuesday, 10/7 3:15 pm Marina Room
	ETX Pharma Discovery | Website	Wednesday, 10/8 10:15 am Marina Room
	Felicitex Therapeutics Discovery | Website	Tuesday, 10/7 11:45 am Marina Room
	GrayBug LLC Discovery | Website	Wednesday, 10/8 11:00 am Marina Room
	Humanetics Corp. Discovery | Website	Tuesday, 10/7 10:30 am Marina Room
	InvivoSciences Inc. Discovery | Website	Tuesday, 10/7 10:15 am Marina Room
	Juvenile Diabetes Research Foundation PAG | Website	Wednesday, 10/8 11:30 am Marina Room
	Leukemia & Lymphoma Society PAG | Website	Wednesday, 10/8 12:00 pm Marina Room
	Makindus Inc. Discovery | Website	Tuesday, 10/7 8:30 am Marina Room
	Meditope Biosciences Discovery | Website	Tuesday, 10/7 1:45 pm Marina Room
	MentiNova, Inc. Discovery | Website	Wednesday, 10/8 10:00 am Marina Room
	Michael J. Fox Foundation PAG | Website	Wednesday, 10/8 9:45 am Marina Room
	Molecular Assemblies Discovery | Website	Tuesday, 10/7 3:00 pm Marina Room
	OncoSynergy Discovery | Website	Wednesday, 10/8 8:45 am Marina Room
	OrgaNext Research Discovery | Website	Tuesday, 10/7 11:30 am Marina Room
	Oricula Therapeutics Discovery | Website	Wednesday, 10/8 10:45 am Marina Room
	ORIG3N Discovery | Website	Tuesday, 10/7 8:15 am Pacific Heights Room
	Rare Cancer Research Foundation PAG | Website	Tuesday, 10/7 9:15 am Marina Room
	Recursion Pharmaceuticals Discovery | Website	Tuesday, 10/7 9:00 am Marina Room
	Relburn-Metabolomics Inc. Discovery | Website	Wednesday, 10/8 11:45 am Marina Room
	Rodin Therapeutics Discovery | Website	Wednesday, 10/8 12:15 pm Marina Room
	Scioderm Discovery | Website	Tuesday, 10/7 8:45 am Marina Room
	Sparrow Pharmaceuticals Discovery | Website	Tuesday, 10/7 8:00 am Pacific Heights Room
	Stemsynergy Therapeutics Discovery | Website	Tuesday, 10/7 11:00 am Marina Room
	Sulfagenix Discovery | Website	Tuesday, 10/7 9:45 am Marina Room
	Syntrix Biosystems Discovery | Website	Tuesday, 10/7 11:15 am Marina Room
	Tunitas Therapeutics Discovery | Website	Wednesday, 10/8 9:15 am Marina Room

Private and Public Presenting Companies

Company	News & Information	Presentation Date, Time (PT), and Location
	AbGenomics International Private  | Website	Wednesday, 10/8 2:30 pm Pacific Heights Room
	ActoGenix NV Private  | Website	Wednesday, 10/8 1:30 pm Marina Room
	Adaptimmune Private  | Website	Wednesday, 10/8 9:30 am Presidio Room
	Alize Pharma Private  | Website	Tuesday, 10/7 10:00 am Pacific Heights Room
	AOBiome Private  | Website	Tuesday, 10/7 4:30 pm Sea Cliff Room
	Apex Therapeutics Private  | Website	Tuesday, 10/7 3:30 pm Marina Room
	Apricus Bioscience APRI-NASDAQ  | Website	Wednesday, 10/8 11:30 am Sea Cliff Room Webcast
	Aptose Biosciences APS-TSE  | Website	Wednesday, 10/8 2:00 pm Sea Cliff Room Webcast
	Argos Therapeutics ARGS-NASDAQ  | Website	Wednesday, 10/8 8:30 am Presidio Room Webcast
	Arno Therapeutics ARNI-OTC  | Website	Wednesday, 10/8 2:30 pm Sea Cliff Room
	Atossa Genetics ATOS-NASDAQ  | Website	Wednesday, 10/8 3:00 pm Sea Cliff Room
	BEAT BioTherapeutics Private  |  Website	Wednesday, 10/8 10:30 am Presidio Room
	Benitec BLT-ASX  |  Website	Tuesday, 10/7 9:30 am Sea Cliff Room
	Berg Private  |  Website	Wednesday, 10/8 9:00 am Pacific Heights Room
	Biocept BIOC-NASDAQ |  Website	Tuesday, 10/7 9:30 am Presidio Room
	BioClin Therapeutics Private  |  Website	Tuesday, 10/7 2:30 pm Pacific Heights Room
	Bio-Path Holdings BPTH-NASDAQ  |  Website	Tuesday, 10/7 10:00 am Presidio Room Webcast
	Blueprint Medicines Private  |  Website	Tuesday, 10/7 11:00 am Sea Cliff Room
	CareDx CDNA-NASDAQ |  Website	Wednesday, 10/8 2:30 pm Presidio Room Webcast
	Catalyst Pharmaceutical Partners CPRX-NASDAQ  |  Website	Tuesday, 10/7 2:00 pm Sea Cliff Room
	Cebix, Inc. Private  | Website	Tuesday, 10/7 8:30 am Pacific Heights Room
	Celladon Corporation CLDN-NASDAQ  | Website	Wednesday, 10/8 11:30 am Presidio Room
	Cerecor Private  | Website	Wednesday, 10/8 10:00 am Sea Cliff Room
	CoLucid Pharmaceuticals Private  |  Website	Wednesday, 10/8 9:30 am Sea Cliff Room
	ContraFect Corporation CFRXU-NASDAQ |  Website	Tuesday, 10/7 3:30 pm Sea Cliff Room Webcast
	Cortendo AB CRTOF-OTC  |  Website	Tuesday, 10/7 3:00 pm Sea Cliff Room Webcast
	Cortice Biosciences Private  |  Website	Wednesday, 10/8 10:00 am Pacific Heights Room
	Critical Outcome Technologies COT-CVE  |  Website	Tuesday, 10/7 9:00 am Sea Cliff Room
	Curis, Inc. CRIS-NASDAQ  |  Website	Tuesday, 10/7 8:00 am Presidio Room Webcast
	CytomX Therapeutics Private  |  Website	Wednesday, 10/8 10:30 am Pacific Heights Room
	Dicerna Pharmaceuticals DRNA-NASDAQ | Website	Wednesday, 10/8 10:00 am Presidio Room
	Enable Injections Private  |  Website	Wednesday, 10/8 11:00 am Pacific Heights Room
	Genkyotex SA Private  |  Website	Tuesday, 10/7 9:00 am Pacific Heights Room
	GlobeImmune GBIM-NASDAQ  |  Website	Wednesday, 10/8 9:00 am Presidio Room Webcast
	GlycoMimetics GLYC-NASDAQ  |  Website	Tuesday, 10/7 1:30 pm Sea Cliff Room Webcast
	Heat Biologics HTBX-NASDAQ  |  Website	Tuesday, 10/7 8:30 am Presidio Room
	Henlius Biotech Private  |  Website	Wednesday, 10/8 2:00 pm Pacific Heights Room
	Immatics Biotechnologies Private  |  Website	Wednesday, 10/8 9:30 am Pacific Heights Room
	ImmunGene Private  |  Website	Wednesday, 10/8 12:00 pm Pacific Heights Room
	Immunovaccine Inc. IMV-CVE  |  Website	Wednesday, 10/8 1:30 pm Sea Cliff Room
	INHIBRx Private  |  Website	Wednesday, 10/8 2:00 pm Marina Room
	Invion Group IVX-ASX  |  Website	Tuesday, 10/7 4:00 pm Presidio Room
	Isarna Therapeutics Private  |  Website	Tuesday, 10/7 4:30 pm Pacific Heights Room
	Juventas Therapeutics Private  |  Website	Tuesday, 10/7 3:00 pm Pacific Heights Room
	LoneStar Heart Private  |  Website	Tuesday, 10/7 1:30 pm Pacific Heights Room
	Lpath Inc. LPTN-NASDAQ  |  Website	Tuesday, 10/7 8:30 am Sea Cliff Room Webcast
	Mast Therapeutics MSTX-NYSE |  Website	Tuesday, 10/7 2:30 pm Presidio Room
	Matinas BioPharma MTNB-OTCBB |  Website	Wednesday, 10/8 12:00 pm Presidio Room Webcast
	Maverix Biomics Private  |  Website	Tuesday, 10/7 11:30 am Sea Cliff Room
	MAX BioPharma Private  |  Website	Wednesday, 10/8 3:00 pm Marina Room
	MetaStat MTST-OTC  |  Website	Wednesday, 10/8 2:00 pm Presidio Room Webcast
	Mirna Therapeutics Private  |  Website	Wednesday, 10/8 11:30 am Pacific Heights Room
	Molecular Templates Private  |  Website	Tuesday, 10/7 4:30 pm Marina Room
	NeoStem NBS-NASDAQ  |  Website	Wednesday, 10/8 11:00 am Presidio Room
	NephroGenex NRX-NASDAQ  |  Website	Tuesday, 10/7 3:30 pm Presidio Room
	Newron Pharmaceuticals SpA NWRN-SWX  |  Website	Wednesday, 10/8 9:00 am Sea Cliff Room
	NexImmune Private  |  Website	Tuesday, 10/7 4:00 pm Marina Room
	NuvOx Pharma Private  |  Website	Wednesday, 10/8 8:30 am Pacific Heights Room
	Ocera Inc. OCRX-NASDAQ  |  Website	Tuesday, 10/7 3:00 pm Presidio Room Webcast
	OncoMed Pharmaceuticals OMED-NASDAQ  |  Website	Tuesday, 10/7 11:00 am Presidio Room Webcast
	OncoSec Medical ONCS-OTC  |  Website	Tuesday, 10/7 9:00 am Presidio Room Webcast
	Oryzon Private  |  Website	Tuesday, 10/7 3:30 pm Pacific Heights Room
	Oxyrane Private  |  Website	Tuesday, 10/7 10:30 am Pacific Heights Room
	Palatin Technologies PTN-NYSE  |  Website	Wednesday, 10/8 11:00 am Sea Cliff Room
	PaxVax Private  |  Website	Tuesday, 10/7 11:00 am Pacific Heights Room
	Pfenex PFNX-NYSE  |  Website	Wednesday, 10/8 8:30 am Sea Cliff Room Webcast
	Polynoma Private  |  Website	Tuesday, 10/7 11:30 am Presidio Room
	Protagonist Therapeutics Private |  Website	Tuesday, 10/7 10:30 am Sea Cliff Room
	Provista Diagnostics Private |  Website	Wednesday, 10/8 1:30 pm Presidio Room
	Radius Health Private  |  Website	Tuesday, 10/7 1:30 pm Presidio Room
	Relypsa RLYP-NASDAQ  |  Website	Tuesday, 10/7 2:30 pm Sea Cliff Room Webcast
	Rexahn Pharmaceuticals RNN-NYSE  |  Website	Tuesday, 10/7 10:30 am Presidio Room Webcast
	RuiYi Private  |  Website	Wednesday, 10/8 3:00 pm Pacific Heights Room
	RXi Pharmaceuticals RXII-NASDAQ |  Website	Tuesday, 10/7 10:00 am Sea Cliff Room Webcast
	Sevion Therapeutics SNTI-OTC |  Website	Tuesday, 10/7 2:00 pm Presidio Room
	Silver Creek Pharmaceuticals Private |  Website	Tuesday, 10/7 2:00 pm Pacific Heights Room
	Sophiris Bio SPHS-NASDAQ |  Website	Tuesday, 10/7 8:00 am Sea Cliff Room Webcast
	Sutro Biopharma Private |  Website	Tuesday, 10/7 4:00 pm Pacific Heights Room
	Tekmira Pharmaceuticals TKMR-NASDAQ |  Website	Tuesday, 10/7 4:00 pm Sea Cliff Room Webcast
	TherapeuticsMD TXMD-NYSE  |  Website	Wednesday, 10/8 10:30 am Sea Cliff Room Webcast
	Theravectys Private |  Website	Tuesday, 10/7 11:30 am Pacific Heights Room
	Tolero Pharmaceuticals Private |  Website	Wednesday, 10/8 1:30 pm Pacific Heights Room
	Trovagene, Inc. TROV-NASDAQ  |  Website	Wednesday, 10/8 3:00 pm Presidio Room Webcast
	TxCell SA TXCL-EPA  |  Website	Wednesday, 10/8 12:00 pm Sea Cliff Room
	Vascular Pharmaceuticals Private |  Website	Tuesday, 10/7 9:30 am Pacific Heights Room
	VivaBioCell Private |  Website	Wednesday, 10/8 2:30 pm Marina Room

*Updated as of 10/3/2014

Biotech/Pharma Company

Corporations or other entities that use biotechnology or related technologies for research and development of products or information.

Discovery Track Company

Corporations qualifying for the Discovery Track rates include only the following: Discovery Track corporations are "pre-emerging" biotech companies, qualifying as seed and A-round companies incorporated after December 31, 2010, that have raised, or are looking to raise, less than $25M total through October 2015. For this event, Discovery Track companies must use biotechnology or related technologies for research and development of drug products or diagnostics. For those companies that want the Discovery Track rate for a company presentation, they also must be first-time presenters at the BIO Investor Forum.

Group Package

Register as a group and save up to 20% off regular registration rates.All biotech and pharma companies are eligible to receive the discounted group registration rates. A minimum of 3 individuals from the same organization must register in order to qualify for the discount. Please note: The group package rate does NOT include a corporate presentation. 

Investors

BIO events attract the most sophisticated investors in the life science community and provide a robust forum for this community to engage in the advancement of promising technologies that improve and save lives. BIO is pleased to provide complimentary registration to qualified investors under BIO’s investor policy which has been clarified for 2015.

Qualified investors are defined as institutional, private equity, angel and venture investors with funds on-hand, whose primary activity is direct investment in research and development companies (e.g., hedge fund, mutual fund, or venture fund). Equity research analysts from investment banking institutions and buy-side analysts also qualify as investors. At BIO’s discretion, qualified investors may also include crowd funding companies and, potentially “accredited investors,” who have gained importance to the biotech industry under the JOBS Act.

The fund name, portfolio type, or other helpful information is needed for BIO to process your registration appropriately. Receipt of complimentary registration for a prior year's event does not automatically qualify a registrant for complimentary registration in 2015.

Academic/Government/Non-Profit (A Code is Required)

Attendees affiliated with accredited government or academic institution. Attendees must show proof through business card or ID on-site. To be eligible for the non-profit registration category, the attendee must show proof of working for an organization that has already received 501(c)(3) status from the Internal Revenue Service. Please send an email to BD_Registration@bio.org to request a code.

Media Registration

Media registration is open to editors and reporters working full time for print, broadcast or web publications with valid press credentials. Advance media registration for the BIO Investor Forum will be available Monday, July 6 – Friday, October 16. Onsite registration will be available starting Tuesday, October 20. 

Service Providers/Suppliers

Corporations or other for-profit entities that provide services or products to biotechnology and other companies. Service providers include investment and merchant bankers and representatives of law, accounting, consulting, contract manufacturers, active pharmaceutical ingredient manufacturers, contact research organizations, real estate development, and economic development organizations. Service providers cannot register with presenting companies unless approved by BIO and do not receive access to BIO One-on-One Partnering^TM. For service providers to access the conference’s online partnering system, the organization must sponsor at a specific level. For information about becoming a sponsor, please contact George MacDougall at 202.962.6689 or gmacdougall(at)bio.org.

For the purposes of registration for any BIO event, conference or meeting, the classification of a registrant as a research and development company, academic & government or a qualifying investor is subject to review by BIO. In its sole discretion, BIO reserves the right to make the determination of the proper classification of a registrant. Depending on this classification, an additional registration fee maybe required. BIO reserves the right to publish materials and restrict conference and/or partnering system access consistent with these determinations.

Tuesday, October 8, 2013, 9:00 a.m. - 9:55 a.m. (Twin Peaks)

Please join us for a special presentation by BayBio in the Twin Peaks room to discuss their recently released whitepaper. This session will consist of a presentation by BayBio, followed by individual presentations by the foundations.

A Guide to Effective Patient Foundation and Life Science Industry Collaborations
By BayBio, featuring Foundation Presentations

Given declining research funds from private and public sources, avoidance of risk investment, increased R&D costs and regulatory challenges, companies and foundations share the need for fresh approaches and more efficient pathways to market. Those life science companies that can harness the power of patient groups will get to the market faster, cheaper and smarter, helping patients and rewarding investors. Though foundations bring urgency, intelligence and resources that can be essential to accelerating key steps in the drug development process, very few companies understand how to foster successful collaborations, overcome differences in their agendas and resources. To help foster more of these partnerships across the industry, BayBio recently completed the first national assessment of such collaborations -- to extract what is working well and what may lead to failure -- from a strong sample set of case studies and relationships. Through this work, BayBio provides a roadmap – both for life science companies and patient groups – of how to explore, form and navigate successful outcomes from the pioneers who led the way.

Presentations:

• 9:00 - 9:15am: Gail Maderis, President & CEO, BayBio
• 9:15 - 9:30am: Sharon Hesterlee, PhD, Vice President Research, Parent Project Muscular Dystrophy
• 9:30 - 9:45am:  Michael Kelly, PhD, Chief Scientific Officer, CureDuchenne
• 9:45 - 10:00am: Audience Q&A

Who's Who

	Sharon Hesterlee, PhD Vice President Research, Parent Project Muscular Dystrophy Dr. Hesterlee is the Vice President of Research for Parent Project Muscular Dystrophy where she oversees research investment and strategy for the organization. Previously she spent 11 years with the Muscular Dystrophy Association (MDA) where she established MDA Venture Philanthropy, designed to be a wholly-owned subsidiary exclusively focused on the discovery and commercialization of therapies for neuromuscular disease. In total, she has brokered and managed over $30M in drug development contracts with industry and other partners. Dr. Hesterlee has also been involved in the planning of numerous meetings on overcoming barriers to therapy development in rare disease.
	Michael Kelly, PhD Chief Scientific Officer, CureDuchenne Dr. Michael Kelly joined CureDuchenne in December 2011 as chief scientific officer. Kelly, a senior pharmaceutical executive, brings more than 25 years experience in drug discovery and development to the organization. He is responsible for advancing drug development programs and identifying new drug targets that exhibit potential to transform the treatment of Duchenne muscular dystrophy. Before joining CureDuchenne, Kelly served as president and U.S. site head of Renovis, Inc. and has held senior positions at Amgen, Inc., Wyeth (Pfizer) and Wellcome (GlaxoSmithKline). Kelly holds a Ph.D. from the University of Southampton (U.K.), held research positions at the University of Michigan and University of Nottingham, is an inventor on more than 100 patents and is widely published in peer reviewed journals.
	Gail Maderis President & CEO, BayBio Gail Maderis is President & CEO of BayBio, the industry organization representing and supporting Northern California’s life science community. As a former biotech CEO, Gail brings deep experience and commitment to supporting the industry through enterprise development, peer-to-peer experience sharing, advocacy and support of education and workforce development. From 2003 to 2009, Gail served as President and CEO of Five Prime Therapeutics, Inc., a privately held protein discovery and development company. At FivePrime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Gail held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology. Gail practiced management and strategy consulting with Bain & Co. She serves on the boards of NovaBay Pharmaceuticals, Opexa Therapeutics, BayBio, the Mayor’s Biotech Advisory Council of San Francisco and the HBS Healthcare Initiative. Gail received a BS in business from UC Berkeley and an MBA from Harvard Business School.

Below is a list of the 2013 BIO Investor Forum speakers. To view or download the full program schedule, please click here.

For questions about programming, please contact Sondra Behan, Manager, Industry research and Programs, Business Development, Biotechnology Industry Organization at: sbehan@bio.org.

Photo	Name and Title	Panel, Date, Time	Location
	Srini Akkaraju, MD, PhD General Partner Sofinnova Ventures	Early Stage Venture Financing – Will Current Trends Continue into 2014? Wednesday, October 9, 2013 3:30 p.m. - 4:25 p.m.	Sunset Court
	Marianne Andreach VP of Strategic Marketing & Product Planning Esperion Therapeutics	The Non-Orphan Panel: Shifting the Focus from Rare Diseases to Primary Care Wednesday, October 9, 2013 9:00 a.m. - 9:55 a.m.	Twin Peaks North/South
	Brian Atwood Managing Director Versant Ventures	Early Stage Venture Financing – Will Current Trends Continue into 2014? Wednesday, October 9, 2013 3:30 p.m. - 4:25 p.m.	Sunset Court
	Jeffrey A. Baumel Partner Dentons	The New Road to IPO in the Age of the JOBS ACT: The Company Perspective Wednesday, October 9th 2:00 p.m. - 2:55 p.m.	Twin Peaks North/South
	Alexis Borisy Partner Third Rock Ventures	Early Stage Venture Financing – Will Current Trends Continue into 2014? Wednesday, October 9, 2013 3:30 p.m. - 4:25 p.m.	Sunset Court
	James B. Breitmeyer, MD, PhD Executive Vice President, Division President Cancer Vaccines  Bavarian Nordic A/S	The Ultimate Rejection: Fighting Cancer with Immunotherapy Tuesday, October 8, 2013 10:30 a.m. - 11:25 a.m.	Twin Peaks North/South
	Mark Charest Vice President New Leaf Venture Partners	IPO Frenzy – Are the GoGo Markets Here to Stay? The Investor Perspective Tuesday, October 8, 2013 12:00 p.m. - 1:25 p.m.	Sunset Court
	Margarita Chavez Director AbbVie Biotech Ventures	Early Stage Venture Financing – Will Current Trends Continue into 2014? Wednesday, October 9, 2013 3:30 p.m. - 4:25 p.m.	Sunset Court
	Steve Conafay, JD Principal The Conafay Group	GAINing Ground in Antibiotics– New Incentives for Biopharma Tuesday, October 8, 2013 2:00 p.m. - 2:55 p.m.	Twin Peaks North/South
	Ashley Dombkowski, PhD Managing Director Bay City Capital	IPO Frenzy – Are the GoGo Markets Here to Stay? The Investor Perspective Tuesday, October 8, 2013 12:00 p.m. - 1:25 p.m.	Sunset Court
	Michael Dybbs, PhD Principal New Leaf Venture Partners	The New Road to IPO in the Age of the JOBS ACT: The Company Perspective Wednesday, October 9th 2:00 p.m. - 2:55 p.m.	Twin Peaks North/South
	David Donabedian Vice President, Venture Investments AbbVie Biotech Ventures	Early Stage Venture Financing – Will Current Trends Continue into 2014? Wednesday, October 9, 2013 3:30 p.m. - 4:25 p.m.	Sunset Court
	Charles C. Duncan, PhD Managing Director & Senior Research Analyst Piper Jaffray	The Non-Orphan Panel: Shifting the Focus from Rare Diseases to Primary Care Wednesday, October 9, 2013 9:00 a.m. - 9:55 a.m.	Twin Peaks North/South
	Michael J. Eichberg, PhD Senior Director, Alliance Management Achaogen	GAINing Ground in Antibiotics– New Incentives for Biopharma Tuesday, October 8, 2013 2:00 p.m. - 2:55 p.m.	Twin Peaks North/South
	Dr. E. Cartier Esham Acting Executive Vice President Emerging Companies, Health and Regulatory Affairs Biotechnology Industry Organization	GAINing Ground in Antibiotics– New Incentives for Biopharma Tuesday, October 8, 2013 2:00 p.m. - 2:55 p.m.	Twin Peaks North/South
	Laurent Fischer, MD Chairman and CEO Jennerex Biotherapeutics	The Ultimate Rejection: Fighting Cancer with Immunotherapy Tuesday, October 8, 2013 10:30 a.m. - 11:25 a.m.	Twin Peaks North/South
	Simone Fishburn, PhD Senior Editor BioCentury Publications	Fireside Chat October 9, 2013 10:30 a.m. - 11:30 a.m.	Twin Peaks North/South
	Lawrence Fong, MD Associate Professor, Department of Medicine (Hematology/Oncology) UCSF Medical Center	The Ultimate Rejection: Fighting Cancer with Immunotherapy Tuesday, October 8, 2013 10:30 a.m. - 11:25 a.m.	Twin Peaks North/South
	Nicholas Franano, MD Founder, President & CEO Novita Therapeutics	Crowdfunding in Healthcare and Biotech - Will it Bridge the "Valley of Death"? Tuesday, October 8, 2013 3:30 p.m. - 4:25 p.m.	Twin Peaks North/South
	Paul J. Hastings President and CEO OncoMed Pharmaceuticals	The New Road to IPO in the Age of the JOBS ACT: The Company Perspective Wednesday, October 9th 2:00 p.m. - 2:55 p.m. Facing Reality: Debating the Conclusions of BioCentury's 21st Annual Back to School Commentary Wednesday, October 9, 2013 12:30 p.m. - 1:25 p.m	Twin Peaks North/South
	James I. Healy, MD, PhD General Partner Sofinnova Ventures	Facing Reality: Debating the Conclusions of BioCentury's 21st Annual Back to School Commentary Wednesday, October 9, 2013 12:30 p.m. - 1:25 p.m	Sunset Court
	Sharon Hesterlee, PhD Vice President Research Parent Project Muscular Dystrophy	A Guide to Effective Patient Foundation and Life Science Industry Collaborations Tuesday, October 8, 2013 9:00 a.m. - 9:55 a.m.	Twin Peaks North/South
	Paul G. Higham CEO immatics biotechnologies GmbH	The Ultimate Rejection: Fighting Cancer with Immunotherapy Tuesday, October 8, 2013 10:30 a.m. - 11:25 a.m.	Twin Peaks North/South
	Thomas E. Hughes, PhD President & CEO Zafgen	Facing Reality: Debating the Conclusions of BioCentury's 21st Annual Back to School Commentary Wednesday, October 9, 2013 12:30 p.m. - 1:25 p.m	Sunset Court
	Thomas Kapsner CEO Morphochem AG	GAINing Ground in Antibiotics– New Incentives for Biopharma Tuesday, October 8, 2013 2:00 p.m. - 2:55 p.m.	Twin Peaks North/South
	J. Joseph Kim President, Chief Executive Officer, Director Inovio Pharmaceuticals	The Ultimate Rejection: Fighting Cancer with Immunotherapy Tuesday, October 8, 2013 10:30 a.m. - 11:25 a.m.	Twin Peaks North/South
	Michael Kelly, PhD Chief Scientific Officer CureDuchenne	A Guide to Effective Patient Foundation and Life Science Industry Collaborations Tuesday, October 8, 2013 9:00 a.m. - 9:55 a.m.	Twin Peaks North/South
	Jan M. Lundberg, Ph.D Eli Lilly Executive Vice President, Science and Technology President Lilly Research Laboratories	Fireside Chat October 9, 2013 10:30 a.m. - 11:30 a.m.	Twin Peaks North/South
	Gail Maderis President & CEO BayBio	A Guide to Effective Patient Foundation and Life Science Industry Collaborations Tuesday, October 8, 2013 9:00 a.m. - 9:55 a.m.	Twin Peaks North/South
	Michael Margolis, RPh Managing Director ROTH Capital Partners	The New Road to IPO in the Age of the JOBS ACT: The Company Perspective Wednesday, October 9th 2:00 p.m. - 2:55 p.m.	Twin Peaks North/South
	Ed Mathers Partner New Enterprise Associates	The Non-Orphan Panel: Shifting the Focus from Rare Diseases to Primary Care Wednesday, October 9, 2013 9:00 a.m. - 9:55 a.m. Facing Reality: Debating the Conclusions of BioCentury's 21st Annual Back to School Commentary Wednesday, October 9, 2013 12:30 p.m. - 1:25 p.m	Twin Peaks North/South
	Erin McCallister Senior Editor BioCentury Publications	Facing Reality: Debating the Conclusions of BioCentury's 21st Annual Back to School Commentary Wednesday, October 9, 2013 12:30 p.m. - 1:25 p.m	Sunset Court
	Evan McCulloch, CFA Portfolio Manager Franklin Templeton Investments	IPO Frenzy – Are the GoGo Markets Here to Stay? The Investor Perspective Tuesday, October 8, 2013 12:00 p.m. - 1:25 p.m.	Sunset Court
	Steven J Mento, PhD President and CEO Conatus Pharmaceuticals	The New Road to IPO in the Age of the JOBS ACT: The Company Perspective Wednesday, October 9th 2:00 p.m. - 2:55 p.m.	Twin Peaks North/South
	Andrew Merickel, PhD Partner Knobbe Martens	Crowdfunding in Healthcare and Biotech - Will it Bridge the "Valley of Death"? Tuesday, October 8, 2013 3:30 p.m. - 4:25 p.m.	Twin Peaks North/South
	Deepa Pakianathan, PhD General Partner Delphi Ventures	Crowdfunding in Healthcare and Biotech - Will it Bridge the "Valley of Death"? Tuesday, October 8, 2013 3:30 p.m. - 4:25 p.m.	Twin Peaks North/South
	Joseph Pantginis, PhD Senior Research Analyst ROTH Capital Partners	The Ultimate Rejection: Fighting Cancer with Immunotherapy Tuesday, October 8, 2013 10:30 a.m. - 11:25 a.m.	Twin Peaks North/South
	Hemai Parthasarathy, Ph.D. Scientific Director Breakout Labs/Thiel Foundation	Crowdfunding in Healthcare and Biotech - Will it Bridge the "Valley of Death"? Tuesday, October 8, 2013 3:30 p.m. - 4:25 p.m.	Twin Peaks North/South
	Eugene Rozelman Managing Director Biopharma Investment Banking, Canaccord Genuity	IPO Frenzy – Are the GoGo Markets Here to Stay? The Investor Perspective Tuesday, October 8, 2013 12:00 p.m. - 1:25 p.m.	Sunset Court
	Susan Schaeffer Editor BioCentury Publications	Facing Reality: Debating the Conclusions of BioCentury's 21st Annual Back to School Commentary Wednesday, October 9, 2013 12:30 p.m. - 1:25 p.m	Sunset Court
	Andrew J. Schwab Managing Partner AM Ventures	Early Stage Venture Financing – Will Current Trends Continue into 2014? Wednesday, October 9, 2013 3:30 p.m. - 4:25 p.m.	Sunset Court
	Brad Spellberg, MD Investigator LA BioMed	GAINing Ground in Antibiotics– New Incentives for Biopharma Tuesday, October 8, 2013 2:00 p.m. - 2:55 p.m.	Twin Peaks North/South
	Gregory C. Simon CEO Poliwogg	Crowdfunding in Healthcare and Biotech - Will it Bridge the "Valley of Death"? Tuesday, October 8, 2013 3:30 p.m. - 4:25 p.m.	Twin Peaks North/South
	Eugene Sun, MD Executive Vice President, Research & Development Rib-X Pharmaceuticals	GAINing Ground in Antibiotics– New Incentives for Biopharma Tuesday, October 8, 2013 2:00 p.m. - 2:55 p.m.	Twin Peaks North/South
	David Thomas, CFA Director, Industry Research & Analysis BIO	IPO Frenzy – Are the GoGo Markets Here to Stay? The Investor Perspective Tuesday, October 8, 2013 12:00 p.m. - 1:25 p.m.	Sunset Court
	Luke Timmerman Vice President, Life Sciences Initiatives Xconomy	Early Stage Venture Financing – Will Current Trends Continue into 2014? Wednesday, October 9, 2013 3:30 p.m. - 4:25 p.m.	Sunset Court
	Effie Toshav Partner Fenwick & West LLP	IPO Frenzy – Are the GoGo Markets Here to Stay? The Investor Perspective Tuesday, October 8, 2013 12:00 p.m. - 1:25 p.m.	Sunset Court
	Michael Wyzga President & CEO Radius Health	The Non-Orphan Panel: Shifting the Focus from Rare Diseases to Primary Care Wednesday, October 9, 2013 9:00 a.m. - 9:55 a.m.	Twin Peaks North/South

Roadmap to Success

9:00 a.m. - 9:55 a.m., Tuesday, October 8th, 2013, Twin Peaks North/South

Given declining research funds from private and public sources, avoidance of risk investment, increased R&D costs and regulatory challenges, companies and foundations share the need for fresh approaches and more efficient pathways to market.  Those life science companies that can harness the power of patient groups will get to the market faster, cheaper and smarter, helping patients and rewarding investors.  Though foundations bring urgency, intelligence and resources that can be essential to accelerating key steps in the drug development process, very few companies understand how to foster successful collaborations, overcome differences in their agendas and resources. To help foster more of these partnerships across the industry, BayBio recently completed the first national assessment of such collaborations -- to extract what is working well and what may lead to failure -- from a strong sample set of case studies and relationships.  Through this work, BayBio provides a roadmap – both for life science companies and patient groups – of how to explore, form and navigate successful outcomes from the pioneers who led the way.

Participating patient advocacy groups currently include ALS Therapy Development Institute and the Parent Project Muscular Dystrophy. Please stay tuned for more information.